Aim: Overexpression of midkine (MK) has been observed in many malignancies. This aim of this study is to screen for suitable antisense oligonucleotides (ASODN) targeting MK in hepatocellular carcinoma (HCC) cells and evaluate its antitumor activity.
Methods: Ten ASODN targeting MK were designed and synthesized. After transfection with ASODN, cell proliferation was analyzed with MTS[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay. In addition, MK mRNA, protein levels, as well as apoptosis and caspase-3 activity were also examined in HepG2 cells. Cell proliferation was then analyzed after treatment with both ASODN and chemotherapeutic drugs.
Results: In this experiment, the ASODN5 among the 10 ASODN showed higher inhibitory activity against proliferation of hepatocellular carcinoma cells in a dose-dependent manner. In HepG2 cells, ASODN5 could significantly reduce the MK mRNA level and protein content. After transfection with ASODN5 for 48 h, accompanied with a decline of survivin and Bcl-2 protein content, a remarkable increase of apoptosis and caspase-3 activity was observed in HepG2 cells. Furthermore, ASODN5 transfer can significantly increase chemosensitivity in HepG2 cells.
Conclusion: Antisense oligonucleotides targeting MK shows therapeutic effects on HCC; ASODN5 has the possibility to be developed as an effective antitumor agent.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1745-7254.2006.00459.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins.
Hipertens Riesgo Vasc
January 2025
Hospital Pharmacist Manager, Pharmaceutical Department, Asl Napoli 3 Sud., Italy. Electronic address:
Statins are crucial for both the prevention and management of atherosclerotic cardiovascular disease (ASCVD). However, even with optimized statin therapy, a significant residual risk of ASCVD remains, highlighting the need for innovative approaches to lipid-lowering therapies (LLT) that more effectively target low-density lipoprotein cholesterol (LDL-C) and other atherogenic lipoproteins. Recently, novel pharmacologic agents have been introduced for the management of dyslipidemia.
View Article and Find Full Text PDFAnti-gene oligonucleotide clamps invade dsDNA and downregulate expression.
Mol Ther Nucleic Acids
December 2024
Department of Laboratory Medicine, Karolinska Institutet, ANA Futura, Alfred Nobels Allé 8, 14152 Huddinge, Stockholm, Sweden.
Anti-gene oligonucleotides belong to a group of therapeutic compounds, which, in contrast to antisense oligonucleotides, bind to DNA. Clamp anti-gene oligonucleotides bind through a double-stranded invasion mechanism. With two arms connected by a linker, they hybridize to one of the DNA strands forming Watson-Crick and Hoogsteen hydrogen bonds.
View Article and Find Full Text PDFuORF-targeting steric block antisense oligonucleotides do not reproducibly increase RNASEH1 expression.
Mol Ther Nucleic Acids
March 2025
Department of Paediatrics, University of Oxford, Headington, Oxford OX3 7TY, UK.
Upstream open reading frames (uORFs) are -regulatory motifs that are predicted to occur in the 5' UTRs of the majority of human protein-coding transcripts and are typically associated with translational repression of the downstream primary open reading frame (pORF). Interference with uORF activity provides a potential mechanism for targeted upregulation of the expression of specific transcripts. It was previously reported that steric block antisense oligonucleotides (ASOs) can bind to and mask uORF start codons to inhibit translation initiation, and thereby disrupt uORF-mediated gene regulation.
View Article and Find Full Text PDFDiscovery and characterization of stereodefined PMO-gapmers targeting tau.
Mol Ther Nucleic Acids
March 2025
Eisai Inc., 35 Cambridgepark Drive, Cambridge, MA 02140, USA.
Antisense oligonucleotides (ASOs) are an important class of therapeutics to treat genetic diseases, and expansion of this modality to neurodegenerative disorders has been an active area of research. To realize chronic administration of ASO therapeutics to treat neurodegenerative diseases, new chemical modifications that improve activity and safety profiles are still needed. Furthermore, it is highly desirable to develop a single stereopure ASO with a defined activity and safety profile to avoid any efficacy and safety concerns due to the batch-to-batch variation in the composition of diastereomers.
View Article and Find Full Text PDFEffect of flow rate on plate height and resolution for antisense oligonucleotides under hydrophilic interaction liquid chromatography conditions.
J Chromatogr A
December 2024
Department of Chemistry, Gustavus Adolphus College, Saint Peter, MN 56082, United States. Electronic address:
Determination of quality attributes of antisense oligonucleotides (ASOs) such as purity, potency, and sequence is challenging due to their relatively large size, polyanionic nature, and large number of synthetic modifications. Chromatography technologies are evolving rapidly to meet these challenges, and one area of particularly rapid change at this time is the use of hydrophilic interaction liquid chromatography (HILIC) for oligonucleotide (ON) separations. Relatively little has been published on the factors that dictate the kinetics of these separations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!